Latest Lead News

Page 14 of 720
Chariot Resources has moved its Nigerian lithium strategy forward with licence approvals, geological mapping and a proposed partner-funded drilling and offtake program. But with A$600,000 in cash, A$3.19 million of borrowings and an estimated 0.75 quarters of funding, the next phase depends on securing more capital.
Maxwell Dee
Maxwell Dee
30 Oct 2026
Cadoux Limited (ASX:CCM) has strengthened the technical case for its high-purity alumina and rare earths portfolio, including battery qualification and new Danube mineralisation beyond its previous exploration envelope. The progress comes with a thinner cash buffer, no listed financing facilities and several commercial milestones still ahead.
Victor Sage
Victor Sage
30 Oct 2026
Adherium delivered a fifth consecutive quarterly record for remote patient monitoring revenue, but ended September with only A$120,000 in cash after a A$3.499 million operating outflow. Post-quarter loans and an AstraZeneca milestone payment have improved near-term liquidity, although further funding remains central to the company’s plans.
Victor Sage
Victor Sage
30 Oct 2026
WA Gold has reported high-grade intercepts from Abercromby, including a narrow peak of 35.21 grams per tonne gold, while launching a 7,200-metre RC campaign aimed at upgrading the project’s resource. Bullabulling has also produced a larger pipeline of exploration targets, but the company had $2.5 million in cash at quarter-end and reported 3.47 quarters of funding at its latest spending rate.
Maxwell Dee
Maxwell Dee
30 Oct 2026
Revolver Resources has secured a A$3 million bridge facility to advance early works at its Dianne copper project, while its quarter-end cash balance covered less than one quarter of reported outgoings. The company still needs a broader package for construction, working capital and offtake before it can reach a Final Investment Decision.
Maxwell Dee
Maxwell Dee
30 Oct 2026
Piche Resources has identified more than 19 new epithermal structures at its Cerro Chacón project in Argentina, including a 2km vein and rock-chip results of up to 10.41 g/t gold and 553.42 g/t silver. The next test is whether those surface signals translate into a coherent mineralised system at depth.
Maxwell Dee
Maxwell Dee
30 Oct 2026
DGR Global ended September with A$54.4 million in cash after investing almost A$5 million in Sunstone Metals, while unpaid Savannah royalties and an Armour Energy appeal add uncertainty. The explorer is redirecting its post-SolGold balance sheet towards copper-gold projects in Queensland and Ecuador.
Victor Sage
Victor Sage
30 Oct 2026
New Age Exploration has logged more than 100 metres of alteration, veining and sulphides at its Wallah Silver Project, but laboratory assays are still needed to establish whether the zone contains silver mineralisation. At Lammerlaw, a standout gold hole is driving a larger 2027 trenching and drilling campaign while cash of $728,000 covers only 0.87 quarters of reported outgoings.
Maxwell Dee
Maxwell Dee
30 Oct 2026
Advance Metals has extended high-grade silver and polymetallic mineralisation at its Gavilanes project in Mexico, including its strongest silver assay to date. The exploration progress comes with a funding question: the company ended September with A$2.106 million in cash, or an estimated 0.97 quarters of funding, and is discussing a capital raising.
Maxwell Dee
Maxwell Dee
30 Oct 2026
Orbminco has completed the main technical studies for its Majestic North gold project, confirming free-milling ore and a potential low-capital Stage 1 route. The next hurdle is financial: the company held A$697,000 at quarter-end, equivalent to 0.59 quarters of reported funding.
Maxwell Dee
Maxwell Dee
30 Oct 2026
Tartana Minerals has accelerated exploration after a shareholder-driven leadership overhaul, but its cash runway is shorter than the time to its next major debt maturity. Assays from Nightflower, copper drilling and regional sampling now carry added significance as the company negotiates refinancing and reviews its stalled copper sulphate operation.
Maxwell Dee
Maxwell Dee
30 Oct 2026
Radiopharm Theranostics is preparing to start a pivotal RAD101 brain-metastases imaging trial in early 2027 after a successful FDA meeting. The clinical progress comes with a sharper funding question: the company reported A$7.46 million in cash against A$10.69 million of quarterly operating outflows, before a subsequent A$8 million tax-incentive-backed advance.
Ada Torres
Ada Torres
30 Oct 2026

Browse the archive

Full archive